Although exome sequencing of LM7 cells did not identify BRCA1 nor BRCA2 gene alterations, LM7 cells exhibited comparable olaparib sensitivity to BRCA2 defective (BRCA2 c.6774delT truncating mutant) CAPAN1 pancreatic ductal carcinoma cells16 (ANOVA p = 0.3757) but significantly greater sensitivity to olaparib than BRCA1 mutant SUM149 cells (ANOVA p = 0.0119), the BRCA1 revertant SUM149 subclone, and a previously validated PARPi resistant BRCA2 revertant CAPAN1 subclone, CAPAN1.B2*.S8 (ANOVA p < 0.0001, Fig. 3A,B). This evidence concerns the gene BRCA2 and pancreatic ductal adenocarcinoma.